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Prospects for Applying Synthetic Biology to Toxicology: Future
Opportunities and Current Limitations for the Repurposing of
Cytochrome P450 Systems
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‡School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia, Brisbane 4072, Australia
ABSTRACT: The 30 years since the inception of Chemical Research
in Toxicology, game-changing advances in chemical and molecular
biology, the fundamental disciplines underpinning molecular
toxicology, have been made. While these have led to important
advances in the study of mechanisms by which chemicals damage cells
and systems, there has been less focus on applying these advances to
prediction, detection, and mitigation of toxicity. Over the last ∼15
years, synthetic biology, the repurposing of biological “parts” in
systems engineered for useful ends, has been explored in other areas
of the biomedical and life sciences, for such applications as detecting
metabolites, drug discovery and delivery, investigating disease
mechanisms, improving medical treatment, and producing useful
chemicals. These examples provide models for the application of
synthetic biology to toxicology, which, for the most part, has not yet
beneﬁted from such approaches. In this perspective, we review the synthetic biology approaches that have been applied to date
and speculate on possible short to medium term and “blue sky” aspirations for synthetic biology, particularly in clinical and
environmental toxicology. Finally, we point out key hurdles that must be overcome for the full potential of synthetic biology to
be realized.
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■ INTRODUCTION
Nature provides a dazzling array of sensitive, ﬂexible, and
exquisitely regulated devices in the form of enzymes, receptors,
regulatory systems for modulating gene expression, signal
transduction pathways, and other genetically encoded “circuits”.
Natural evolutionary processes have generated a degree of
sophistication which engineers can barely dream of emulating.
Therefore, it is not surprising that eﬀorts are now being made
to “synthesize biology”, i.e., to recombine existing or
engineered biological “parts” (bioparts or “bio-bricks”) to
create complex devices for deﬁned purposes in many areas of
biology and chemistry. Toxicology provides fertile ground for
the application of this emergent discipline in exploiting the
biological sensors (receptors, binding proteins, enzymes, and
transporters), signal transduction pathways (nuclear and other
receptor-linked systems for regulating gene expression), and
eﬀector systems (enzymes and transporters) that have evolved
in Nature to respond to chemical challenge. The aim of this
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perspective is to explore how synthetic biology might be used
to address problems in toxicology, focusing on cytochrome
P450 systems as a model for other proteins of toxicological
relevance.
Synthetic biology can be deﬁned broadly as the design,
engineering, and/or recombination of biological parts, devices,
and systems for useful ends (http://syntheticbiology.org/).
The elements of the “devices” and genetically engineered
“machines” produced by synthetic biology are usually based on
and inspired by natural biological elements, but often
incorporate design principles derived from engineering.
Synthetic biology relies on the central importance of nucleic
acids in encoding, regulating, and controlling biological
systems, so while the idea of adapting Nature to anthro-
pocentric ends is not new, it is only in the past decade that
techniques for eﬃcient, large scale DNA synthesis have allowed
the facile re-engineering of biological molecules.
The redesign of biological systems can be considered at
several levels of increasing complexity:1 protein engineering;
metabolic engineering; synthetic circuits and systems; the
redesigning of minimal chromosomes and cells; and bio-
orthogonal systems (sometimes termed “xenobiology”2 or
xenobiochemistry, terms that are somewhat ambiguous in the
context of toxicology). The focus of this perspective will be on
the ﬁrst three of these levels, the last two being less relevant to
the application of synthetic biology to toxicology. There is
considerable overlap between the established ﬁeld of
biotechnology and the emerging discipline of synthetic biology.
For the purposes of this perspective, no line will be drawn
between synthetic biology and protein or metabolic engineer-
ing; while there is some debate over the precise scope and
deﬁnition of synthetic biology, eﬀectively there exists a
continuum between the engineering of parts, cells, and devices,
and we believe that any subdivision is arbitrary due to the
dependence of more complex synthetic biology on the basic
engineering of the component parts.
Mechanistic toxicology, a major focus of Chemical Research in
Toxicology, relies on the means for reproducing, detecting, and
dissecting the eﬀects of chemicals at the molecular, cellular, and
tissue levels. Indeed toxicology represents one of the ﬁrst
applications of synthetic biology outside pure research in the
development of reporter assays for the induction of P450s by
drugs and other chemicals. While not deﬁned as synthetic
biology at the time, linking the gene for a nuclear receptor in
tandem with that of a reporter gene and using the natural trans-
acting factors in a cell line to detect inducers combines many of
the elements of synthetic biology circuits. In clinical toxicology,
biosensors for the detection of drugs and other chemicals hold
promise for improving both treatment with drugs and detection
of poisoning. On the other hand, biologically based systems can
be envisaged for the more eﬀective treatment of overdose.
Parallel opportunities can be explored in the detection of
toxicants and the bioremediation of chemical spills in the
environment. Finally, synthetic biology can play a supportive
role in facilitating toxicological studies, e.g., in engineering of
systems for biosynthesis of metabolites for structural character-
ization and safety assessment.
In the following sections, we explore the potential for
synthetic biology to address questions in toxicology, improve
the assessment of toxic responses, and mitigate the eﬀects of
toxic substances. We focus on the development of systems
based on cytochromes P450 (P450s), the major metabolic
system for the clearance of xenobiotics in man, as a model for
the broader application of synthetic biology approaches in the
ﬁeld of toxicology. Four general areas emerge in which
synthetic biology can be used to address toxicological
problems: in the development of pharmaceuticals, in environ-
mental toxicology, and in clinical and experimental toxicology.
“Bioparts”, devices and systems of increasing complexity,1 can
be envisaged in each of these areas. We aim to examine what
has been done to date, focusing on key studies rather than
attempting a comprehensive review of the literature but also to
suggest opportunities where “blue sky” research could lead to
useful advances in the next decade, and to highlight important
issues that must be addressed before these can be realized.
■ ENGINEERED ENZYMES AND BIOCATALYTIC
SYSTEMS: SYNTHETIC BIOLOGY IN THE
PHARMACEUTICAL INDUSTRY
The safe development of drugs requires that the metabolism of
lead compounds be characterized both qualitatively and
quantitatively in terms of the metabolites produced and the
enzymes responsible for clearance. The latter is critical for
anticipating inhibitory drug−drug interactions where two drugs
compete for the same metabolic enzyme. Additionally, testing
the ability of new chemical entities to induce drug-metabolizing
enzymes can indicate which compounds may accelerate the
metabolism of coadministered medications. Finally, the
bioactivity of metabolites may also need to be assessed
depending on their quantitative importance and chemical
nature. Thus, several separate issues arise: the need to identify
the relevant enzymes that catalyze the clearance of a candidate
drug (reaction typing), the need to assess the potential for
induction, and the requirement for signiﬁcant amounts of
metabolites for structural identiﬁcation and toxicological
evaluation. P450 enzymes are center-stage in all of these issues
as the principal enzymes responsible for the metabolic
clearance of drugs.
Recombinant Systems for Preclinical Drug Develop-
ment. Since the 1990s, recombinant enzymes have been used
widely in the pharmaceutical industry for preclinical drug
development studies. P450s and other proteins relevant to
toxicology have been expressed in heterologous systems
principally for the assessment of xenobiotic biotransforma-
tion.3−17 Coexpression systems18−21 including both the P450
and its redox partner(s) allowed functional reconstitution of
P450 activities in the microbial host. These have been the
subject of reviews and will not be detailed further here.22−24
Likewise, the cloning of xenobiotic response elements and their
cognate transcription factors enabled the development of
reporter gene assays from the late 1990s, a point that will be
discussed further in a later section.
These early studies provided the foundation for biocatalytic
systems to address a critical bottleneck in drug development,
namely, the synthesis of authentic metabolites for structural
characterization and toxicological evaluation. Traditional
medicinal chemistry approaches often fail to provide metabo-
lites with the desired stereochemistry in good yield, problems
that can potentially be overcome by using metabolic enzymes
to modify the parental structure. Ideally, this is possible with
the native enzymes responsible for the generation of the
metabolites in question in vivo,25,26 but in practice, bioreactors
containing unmodiﬁed enzymes are limited by the total
turnovers that can be achieved with unstable, promiscuous,
low eﬃciency catalysts such as the drug-metabolizing P450s.
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Moreover, it is often useful to enhance the production of minor
metabolites relative to major ones to improve their recovery.27
Biocatalytic Systems for Metabolite Biosynthesis.
Protein engineering is a fundamental enabling technology for
synthetic biology and a well-established tool for biotechnology
that has been applied to improve the substrate speciﬁcity,
stability, and catalytic eﬃciency of P450s for industrial use.
Most studies have concerned P450BM3 (CYP102A1), a
“workhorse” P450 renowned for its high turnover rate on
native substrates and ease of production.28 Studies by various
laboratories,29−34 which have been reviewed extensively
elsewhere,35,36 have optimized CYP102 enzymes for use in
bioreactors culminating in a set of CYP102 mutants that have
been applied commercially.30 Less attention has been paid to
engineering the conventional “drug-metabolizing” P450s, but
scope exists for further application of these forms due to their
favorable substrate speciﬁcity, especially in regard to their
stereo- and regioselectivity. Two key limitations exist to both
types of biocatalysts: the stability of the enzymes, both to
temperature and oxidative damage due to uncoupling during
substrate turnover; and the eﬃcient supply of electrons.37
The interaction of P450s with their redox partners is critical
for eﬀective catalysis but typically the most diﬃcult aspect of
systems to optimize. Coexpression and eﬀective coupling of the
P450 with its cognate NADPH:P450 reductase (CPR) are
generally important for eﬃcient reaction kinetics in heterolo-
gous expression systems,18,19 and various means of achieving
this have been developed (Figure 1). Fusion proteins, in
particular, are attractive for multiple reasons38 (Figure 1B). In
theory, tethering the P450 and reductase proteins should
enhance the rate of electron transfer from NADPH to the P450
since the eﬀective local concentration of each domain is
increased by the fusion. Consistent with this idea, cytochrome
P450BM3 from Bacillus megaterium, a naturally occurring P450-
Figure 1. Alternative redox systems for supporting P450 catalysis. (A) Coexpression of P450 with its cognate redox partner in membranes; (B)
fusion of the P450 with its redox partner; (C) the Puppet system, where P450cam and its redox partners, Pdx and PdR, are fused to the separate
elements of the annular PCNA structure;55 (D) the Puppet system modiﬁed by the fusion of phosphite dehydrogenase monomers (shown in
orange), enabling cofactor regeneration and self-assembly of catalytic units into a higher-order, multimeric, hydrogel structure;56 and (E) P450
supported by photosystem I.70 For simplicity, the remainder of the photosynthetic electron transport chain is not shown.
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reductase fusion, exhibits the fastest characterized turnover of
any P450 (∼17,000 min−1 for hydroxylation of arachidonic
acid) and is often cited as an example of the potential beneﬁts
of a P450-reductase fusion.39 Mammalian P450s have been
expressed as fusion proteins joined to the NADPH:P450
reductase enzyme40−45 with mixed results. Overall, fusions have
failed to yield the expected improvements in speciﬁc activity; in
most cases, the rate of P450 catalysis was comparable with or
decreased compared with that obtained from reconstitution or
coexpression of the separate P450 and CPR domains,44,46 and
evidence has been obtained that intermolecular electron
transfer occurs in addition to or in place of electron transfer
between the fused domains of a single polypeptide. This has
been interpreted as indicating that intramolecular electron
transfer or P450 function is not well coupled in these fusion
proteins, potentially due to suboptimal positioning of the NPR-
P450 interaction interface or misfolding, leading to many eﬀorts
(for the most part, unpublished) to optimize the connecting
linker.47−49
Besides the potential for enhanced reaction kinetics,
expression of P450-reductase fusion proteins could simplify
the functional retargeting of P450s to diﬀerent organelles in
eukaryotic hosts, enable the use of alternative electron donors
besides soluble NADPH, and potentially simplify combinatorial
cloning eﬀorts if a reliable reductase fusion module could be
developed rather than trial-and-error testing of fusions. In this
regard, the LiCRED and related systems are promising50−52 but
need to be tested with a wider range of P450s.
Immobilized Enzyme Systems. Enzyme immobilization is
attractive in the context of metabolite production systems. In
addition to the kinetic advantages of colocalizing P450s and
their redox partners described above, colocalization of a high
concentration of active sites can facilitate spatially eﬃcient
turnover of substrates and improve reuse and product
separation53 (concepts of enzyme immobilization are reviewed
in54). Importantly, colocalization of diﬀerent domains can allow
optimization of their relative position to enhance electron
transfer, as exempliﬁed in new biological scaﬀolding ap-
proaches. P450cam from Pseudomonas putida functions in a
tripartite system receiving electrons from putidaredoxin
reductase (PdR) via putidaredoxin (PdX). These three proteins
were colocalized using a self-assembling system that exploits the
heterotrimeric proliferating cell nuclear antigen (PCNA) from
Sulfolobus solfataricus in a system, described as PCNA-utilized
protein complex of P450 and its two electron transfer-related
proteins (PUPPET)55 (Figure 1C). The P450 and its two
redox partners were each expressed as fusions with a PCNA
monomer and when combined in equimolar concentrations in
vitro, the PCNA monomers assembled as heterotrimers to
colocalize the fused catalytic components. Optimization of both
the relative position of the three domains and the aﬃnity
between the elements of the scaﬀold was necessary, but
ultimately, the resulting system supported faster reaction rates
(measured as NADH or oxygen consumption or product
formation) than a mixture of the three individual proteins
without the PCNA fusion tags.
Recently, the PUPPET system was developed further into a
supramolecular scaﬀold where the PUPPET heterotrimers were
cross-linked using fusions to homodimeric phosphite dehydro-
genase56 (Figure 1D). In this system, the PCNA monomers
bear P450cam, PdX, or PdR at the C-terminus and a phosphite
dehydrogenase at the N-terminus. The self-assembling
heterotrimers become cross-linked through the dimerization
of phosphite dehydrogenase. Furthermore, the system provides
a cheap NADH regeneration mechanism (via oxidation of
phosphite) colocalized with PdR. The oligomeric protein
complexes form a gel that is insoluble in water, and although it
has a slower kcat than the PUPPET system, the potential
cofactor savings, and stability of the system (it can be recycled a
limited number of times) make it attractive for the bulk
generation of metabolites. The PUPPET system has also been
used very recently to facilitate the immobilization of P450cam,
PdX, and PdR on a solid support.57 Retention of the proteins
on the support was promoted by engineering disulﬁde bonds
between the PCNA monomers. The approach was successfully
applied to intact P450BM3, but separation of the enzyme into
individual domains appeared to compromise electron transfer.57
Immobilization has also been developed in vivo in engineered
E. coli cells. Previously, E. coli have been engineered to produce
poly-3-hydroxybutyrate (PHB), a biopolymer that forms
insoluble granules inside the host cell.58,59 P450BM3 was fused
to the PHB-associated phasin protein, which localizes to the
surface of intracellular PHB granules.60 Because of the
insolubility of PHB, granules decorated with functional
P450BM3 could be recovered from lysed E. coli via
centrifugation. Solar-powered in vitro P450BM3 catalysis was
subsequently demonstrated by fusing a mutant P450BM3 lacking
the reductase domain to PHB granules and reducing the
catalytic domain with the light-driven Eosin Y method that is
described in detail in the following section.61
These immobilization methods potentially oﬀer dramatic
cost reductions for bulk in vitro catalysis and are highly
accessible and relatively simple to manufacture, relying entirely
on recombinant E. coli and self-assembly of the protein
components. It remains to be seen whether these systems can
also be used with membrane-associated mammalian P450s.
More Complex Systems: Bioreactors Supported by
Diﬀerent Redox Systems. The diﬃculty in reconstituting
P450s with redox partners plus the expense of the cofactor have
motivated the development of alternative means of supporting
catalysis. The peroxide shunt can be used with P450s acting as
peroxygenases.62 However, the presence of peroxides (either
supplied intentionally or generated by uncoupling using any
mode of electron transfer) typically damages the enzyme and
reduces total turnover. Rather, one of the most promising areas
of research is in light-driven P450 reactions. P450BM3 catalysis
can be driven by a rubidium(II) photosensitizer covalently
attached to the P450 domain in close proximity to the heme.
These hybrid systems are functional in the absence of the
reductase domain or NADPH.63 Attachment of the prosthetic
rubidium requires mutation of the enzyme and in vitro post-
translational modiﬁcation. While innovative and catalytically
eﬃcient toward native substrates, this approach is likely to have
a limited breadth of application: it can only be used with in vitro
systems and to-date has only been implemented with
derivatives of P450BM3.
64,65 It is not clear whether this approach
would be successful with membrane-associated eukaryotic
P450s.
A simpler and potentially cheaper and more versatile method
of light-driven P450 biocatalysis uses Eosin Y, a photosensitive
ﬂuoroscein dye.66 Photosensitized Eosin Y has been demon-
strated as an eﬀective mediator to transfer electrons to the P450
heme from a low-cost electron donor (triethanolamine). The
main drawback of this system is the apparent decreased
eﬃciency of electron transfer to the heme iron: O-deethylation
of 7-ethoxycoumarin by P450BM3 was considerably slower using
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the Eosin Y system than when supplied with NADPH.
However, the Eosin Y photoreduction concept proved to be
highly versatile. The system was implemented with human
P450s 1A1, 1A2, 1B1, 2A6, 2E1, and 3A4, and catalysis was
demonstrated against a suite of drug and steroid probe
substrates.66 Furthermore, Eosin Y and triethanolamine are
readily taken up by E. coli, and the method was functional when
used with whole E. coli cells expressing P450s. While the
reduced rates of catalysis make this system undesirable for
enzymatic characterization, the reduction in cofactor costs
makes it appealing for large scale and bulk biocatalysis
applications. At the time of writing, NADPH is approximately
200,000 times more expensive on a molar basis than
triethanolamine. The concentration of Eosin Y can potentially
be optimized as a function of reagent cost and catalytic rate, as
the dye is not consumed by the reaction, and the catalytic rate
appears to increase with increasing Eosin Y concentration.
Experiments with plant P450s provide another, potentially
useful paradigm. Fundamental studies demonstrated that
certain P450s could be reconstituted with photosystem I in
an in vitro, thylakoid membrane preparation, and that the P450
was reduced by ferredoxin in a light-dependent manner.67−69
When CYP79A1 was reconstituted with photosystem I, the
P450 turnover rate was almost twice that seen in
reconstitutions of puriﬁed P450 and CPR. More recently, the
ferredoxin was fused to the C-terminus of the P450 via a
ﬂexible linker domain, and this construct was demonstrated to
be functional even in the absence of soluble free ferredoxin.70
The authors sought to test whether further gains could be made
in the eﬃcient use of photosynthesis-derived electrons for
P450-mediated biocatalysis. The fusion construct resulted in
superior reaction kinetics under conditions of high ionic
strength (>100 mM) as compared with the unfused system
where ferredoxin was added separately but was less eﬃcient at
low ionic strengths. When expressed in tobacco plants, the
fusion enzyme supported increased metabolism of tyrosine to
the CYP79A1 metabolite p-hydroxy-phenylacetaldoxime and
the glucosylated form, p-glucosyloxy-phenylacetaldoxime. The
small size of the ferredoxin domain and the success of using a
ﬂexible linker suggest that the ferredoxin fusion module could
be coupled to other P450 enzymes without aﬀecting P450
folding or membrane association. While this work shows the
potential for light-driven P450-mediated biosynthetic processes,
it is yet to be seen if this system will be useful with other P450s,
including those of toxicological relevance, such as forms from
the CYP1−3 families.
The recent innovations in provision of reducing power to the
cytochrome P450 are promising steps toward cheap, easy to
implement, universal reducing systems for use in engineered
whole cells and in vitro systems. While these are likely to have
the most signiﬁcant impact in the short term in the production
of drug metabolites, longer term applications can be envisaged
in other areas of toxicology such as bioremediation. In this
context, plant-based systems may be especially relevant.
■ SYNTHETIC BIOLOGY IN ENVIRONMENTAL
TOXICOLOGY: BIOREMEDIATION
The ability of P450 enzymes to oxidize and contribute to the
degradation of persistent organic pollutants (POPs) is well-
known.71 P450 activities have been identiﬁed in the degradation
of polycyclic aromatic hydrocarbons (PAHs)72 and polychlori-
nated biphenyls (PCBs),73 agricultural chemicals including
organophosphates, and explosives such as trinitrotoluene
(TNT)74 and 1,3,5-trinitro-1,3,5-triazacyclohexane (otherwise
known as 1,3,5-trinitrohexahydro-s-triazine; cyclonite; hexogen;
or RDX).75
The scientiﬁc literature of the past 10 years has seen a
continual disclosure of new P450-mediated reactions with
potential bioremediation applications, including the discovery
of new P450s involved in oxidation of high molecular weight
PAHs76 and the agricultural fungicide, propiconazole.77 While
the promiscuous catalytic activity of mammalian xenobiotic-
metabolizing P450s often extends to environmental pollu-
tants,78,79 to date, more useful pollutant-degrading P450s have
been identiﬁed in microorganisms isolated from contaminated
environments.
The classical method of isolating new enzymatic functions
from environmental samples is a powerful and unambiguous
approach that highlights the potential utility of engineered
P450 systems in the environment. However, it is also time-
consuming and restricts the search space to organisms that can
be cultured easily in the laboratory. The emergence of
metagenomics has massively expedited the identiﬁcation of
genes associated with the degradation of environmental
pollutants. For example, P450 sequences and other genes
associated with alkane degradation were identiﬁed across
several genera in metagenomic studies of diesel-contaminated
sites.80,81 Through metagenomic approaches, candidate en-
zymes from thousands of organisms can be identiﬁed without
the need for microbial culture and isolation. With continued
reductions in the cost of gene synthesis, it is becoming more
straightforward to synthesize multiple candidate sequences for
testing in laboratory organisms like E. coli.
While it is clear that environmental contamination itself can
select for pollutant-degrading organisms that harbor useful and
interesting P450s, naturally occurring bioremediation does not
necessarily occur on an acceptable time scale for clean up of
pollutants. Some plants exhibit a degree of tolerance toward
POPs and an ability to remove them from the soil, thereby
providing a potential alternative to natural microbial bio-
remediation, but many plant tissues accumulate rather than
degrade the compounds of concern. For example, wild
blackberry at a contaminated industrial site was observed to
accumulate high molecular weight PAHs,82 and some plant
species extract RDX from contaminated soil but have a limited
ability to metabolize the compound.83 Phytoextraction of POPs
without catabolism risks accumulation in the food chain
(through consumption by herbivores) or returning the POPs
to the soil if the entire plants including roots are not harvested
and destroyed. Therefore, one of the most promising strategies
for bioremediation of POPs is the engineering of organisms,
particularly plants, with non-native catabolic enzymes.
Early eﬀorts, particularly from the Ohkawa group, proved the
feasibility of heterologous expression of P450s in plants84−90
and phytoremediation of environmental chemicals, speciﬁcally
herbicides. Subsequently, transfer of the RDX-degrading P450
to Arabidopsis thaliana alleviated the phytotoxic eﬀects of RDX-
contaminated soil at concentrations up to 2000 mg RDX/kg
soil.75 Coexpression of an RDX-degrading P450 with a TNT-
degrading nitroreductase in A. thaliana resulted in resistance to
both compounds at concentrations comparable with those
found at contaminated sites, and accumulation of RDX and
TNT in aerial tissues was decreased.91 Several P450 enzymes
have also been engineered for enhanced activity in oxidation of
POPs including PAHs,92,93 polychlorinated benzenes,94 and
monosubstituted benzenes.95
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■ BIOSENSORS
Detection of chemicals in the environment should also be
amenable to synthetic biology approaches, and the engineering
of biosensors to detect speciﬁc chemicals has additional
potential applications in medicine and other ﬁelds. Most
biosensors for monitoring chemicals in the environment or in
vivo utilize naturally occurring microbial proteins known to
bind the ligand of interest. However, in principle, engineered
P450s could also be employed in biosensor devices to detect
and monitor chemicals in various milieux, for both environ-
mental and clinical toxicology applications. Xenobiotic-
metabolizing P450s, by virtue of their broad substrate
speciﬁcity, provide a useful starting material for the develop-
ment of specialized binding proteins for speciﬁc chemicals and
will be a useful addition to the battery of nucleic acid- and
protein-based systems in development for chemical sensing.96
Such engineered P450 systems could have broad applications in
the detection of chemicals of many types.
The electrochemical properties of cytochrome P450 enzymes
provide a means to monitor the P450 catalytic cycle
electronically, and several P450 biosensor systems have been
developed along these lines.97−101 Much of the research in this
area102,103 has been motivated by the desire to deliver electrons
to P450s using electrodes rather than consuming expensive
cofactors during catalysis; where successful, catalysis can be
achieved either (1) by the generation of hydrogen peroxide by
reduction of Fe(II)-O2 at the electrode and its subsequent use
to generate the high valent, active, oxygenating species of P450
(compound I) via the peroxide shunt (which can occur in the
absence of any redox partner) or (2) in a way that more closely
mimics the native system, i.e., via reduction of the P450 by CPR
reduced at the electrode.103,104 It is unclear what the working
lifetime of such systems would be if employed for biocatalysis,
especially in light of the continual production of hydrogen
peroxide at the electrode surface via electrolysis of oxygen.
Therefore, it would be advantageous to engineer forms of the
enzyme that are resistant to oxidative damage and also more
thermostable for further development of such systems.
Arguably, given concerns over sensitivity to damage by
peroxide, the application of electrochemical systems purely as
biosensors may be more realistic in the short term. The
ultimate goal of P450 biosensors is in point-of-care diagnostics
or monitoring of environmental pollutants in the ﬁeld, but
devices have also been proposed for screening for drug−
enzyme interactions in drug development. The majority of
proposed P450-based biosensors use immobilized enzymes and
measure changes in the electrochemical properties of the P450
upon interaction with a ligand. These experimental biosensors
that interface enzymes with electrical circuits have been
discussed in detail elsewhere, and the reader is directed to a
number of excellent reviews.105−109
One important application of such devices is in therapeutic
monitoring of drugs for which the eﬀects are not easily detected
or titrated based on response. The detection of such drugs
currently relies on resource-intensive blood tests. For drugs
such as immunosuppressive agents and anticonvulsants, which
show a small therapeutic window and large interindividual
variability in pharmacokinetics, there is a clear need for
convenient, minimally invasive devices that sense drug
concentrations and report them in terms of an easily detected
output, similar to a blood glucose monitor. As examples,
immobilized enzymes have been investigated for the measure-
ment of the drugs, indinavir,110,111 caﬀeine,112 codeine,113
naproxen,114 ethambutol,115 phenobarbital,116 sertraline,117 and
the illicit drug cocaine.118,119 Analogous approaches have been
used for environmental monitoring, e.g., of bisphenol A,120 2,4-
dichlorophenol,121 pesticides,122 and benzo[a]pyrene.123
In an extension of the basic electrochemical biosensor idea,
Rusling and co-workers have developed extensive technology
based on measuring genotoxicity as well as P450 activity in
various electrochemical and electrochemiluminescent systems.
The majority of these systems use native enzyme preparations,
such as puriﬁed enzymes or liver microsomes, which are
incorporated with or without DNA into thin layers of
alternating charge starting with a synthetic polyion using a
layer-by-layer ﬁlm fabrication technique (reviewed in ref 106).
Other groups have used similar approaches to measure DNA
damage.124
To date, most studies have essentially involved coupling of
more or less native (i.e., unengineered) enzyme preparations to
electrodes, but there is no reason why such devices should be
limited to existing enzymes. In theory, the promiscuous drug-
metabolizing P450s could be evolved in vitro to bind with
higher speciﬁcity to chemicals of interest and to generate a
greater electrochemical response. Also, as with electrocatalytic
systems, the limited stability of the currently available enzymes
means that the shelf life and therefore the economic feasibility
of such devices is determined by their half-life. Fortunately,
thermostability is another property that can be improved by in
vitro evolution.125
One novel approach combines the amperometric chip
biosensor concept with whole cells.126 Whole E. coli expressing
P450BM3 were suspended in a buﬀer solution containing glucose
in an electrochemical cell and monitored with a potentiostat for
changes in current due to the product of the oxidation of
aniline upon addition of inhibitors (including alternative
substrates). The system was validated by comparison with
puriﬁed P450BM3. The ability to use intact E. coli in this system
greatly enhances the ﬂexibility of electrochemical P450
biosensors. In addition to eliminating NADPH costs, enzyme
puriﬁcation becomes unnecessary, and fresh catalytic material
can be prepared with minimal eﬀort. Furthermore, it suggests
the possibility of a ﬂexible system where diﬀerent P450
enzymes expressed in E. coli can easily be substituted in order
to screen for diﬀerent compounds, given an appropriate
electroactive, probe substrate. The system has not yet been
validated with human drug-metabolizing P450s; however, such
devices may be of use in drug development to screen for
inhibitors of drug metabolism by P450s or in environmental
monitoring. The sensitivity may be poorer with slower
enzymes, particularly in cases where expression in E. coli is
poor. However, this concept has potential for developing
compound-screening devices using other P450 enzymes.
The redox characteristics of P450s or their products provide
one end point for biosensors, and the interest in electro-
chemical biosensors relates to the easy integration with
amperometric devices developed for other biosensors, e.g,
blood glucose monitors. However, other characteristics of
P450s provide scope for detecting ligands in alternative ways,
e.g., plasmon resonance127,128 or oxygen consumption.129,130
For example, the spin shift induced by the binding of a ligand to
a P450 could be detected colorimetrically as a change in the
absorbance of visible light in a speciﬁc wavelength range. In
another, more complex example, an E. coli-based biosensor has
been engineered that could potentially be used for the
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detection of any ligand metabolized by a P450 on the basis of
NADPH consumption.131 The soxR gene encodes an iron−
sulfur cluster repressor protein that, when in a reduced state,
represses the expression of the soxS gene. The soxR protein is
maintained in a reduced state by the activity of native NADPH-
dependent reductase enzymes, and a decrease in the availability
of NADPH results in oxidation of soxR and subsequent
expression of SoxS. By placing a ﬂuorescent protein under the
Figure 2. Levels of complexity of synthetic biology approaches that could be applied to toxicological problems with examples of possible devices.
Systems can be conceptualized ranging from simple eﬀectors comprising a catalytic complex to a sequence of interacting bioparts that enable an
appropriate response to be generated to a speciﬁc stimulus. Simple sensor-type arrangements are deﬁned here as systems where a biopart is linked to
some physicochemical transducer that can allow a signal to be generated in response to a change in the biopart elicited by interaction with a speciﬁc
chemical. Such systems can also be conceived of operating in reverse, as eﬀectors, where a physicochemical (e.g., electrical) signal is used to elicit a
change in the biopart to eﬀect a speciﬁc outcome, e.g., the supply of electrons to a P450 to enable catalysis.
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control of the soxS promoter, the activity of non-native
NADPH-consuming enzymes, such as P450s, can be detected
upon addition of their corresponding substrates due to a
sudden decrease in the available NADPH pool. This type of
system could be used with engineered P450s speciﬁc for ligands
of interest. However, it would be important to ensure that this
type of biosensor was both highly specialized and well coupled,
as many ligands are known to trigger enhanced NADPH
oxidation by promiscuous P450s, and this is not necessarily
coupled to substrate oxidation.
■ GENETICALLY ENCODED RESPONSE CIRCUITS:
AUGMENTED TOXICOLOGICAL SCREENING
SYSTEMS
Genetic response circuits, such as the one in the soxS example
above, illustrate the next step up in complexity of synthetic
biology systems (as depicted in Figure 2), and there are a
number of existing examples of simple response circuits used
for screening for toxic eﬀects of chemicals. These can be
understood in terms of a simple paradigm linking some input
(e.g., the presence of a particular chemical), through a sensor
and transducer, to an output (e.g., expression of a reporter
protein).132 For many years, recombinant reporter gene assays
have been used to predict the potential of new chemical entities
to induce P450 expression since this can alter the metabolism
of coadministered drugs causing adverse drug interactions.
These assays typically link the upstream regulatory sequences
for a gene of interest (usually a P450) to some easily detected
reporter protein, such as a ﬂuorescent protein. Ligands are
screened in an appropriate host cell for the ability to alter the
binding of nuclear receptors/transcription factors to regulatory
elements, aﬀecting the expression of the reporter gene. As well
as in drug development, this concept has been applied to
environmental monitoring. The presence of polycyclic aromatic
hydrocarbons and related pollutants in aquatic environments
can be assessed by the induction of P450s in ﬁsh. Thus, a
transgenic zebraﬁsh has been developed, in which GFP
expression is regulated by the CYP1A1 promotor, allowing
detection of polychlorinated biphenyls.133
Bioactivation of chemicals by P450s and other enzymes has
also been studied using genetic response circuits. The most
notable example is the SOS response which results in
widespread transcriptional activation in response to DNA
damage. Several systems have been developed where reporter
genes are activated by the SOS response. Indeed, shortly after
the development of human P450 expression in E. coli, P450
metabolites from procarcinogen assays were screened for
activation of the SOS response134 in a Salmonella typhimurium
strain engineered so that DNA damage triggered the expression
of β-galactosidase.135 Subsequently, human P450s 1A1, 1A2,
1B1, 2C9, 2D6, 2E1, and 3A4 were each expressed in S.
typhimurium along with the human CPR, enabling catalysis and
response activation within a single system.136,137 The SOS-β-
galactosidase system has also been optimized in E. coli.138
Although β-galactosidase is easily assayed and can be used in
very high throughput with qualitative blue/white screening on
agar plates, its applications are limited compared with other
systems designed for quantitative high throughput screening. E.
coli have been engineered to produce luciferase139 and green
ﬂuorescent protein140−142 in response to direct SOS activation
by mutagens, but to our knowledge, these systems have not
been coupled to enzymatic bioactivation systems (e.g.,
recombinant P450s) to date.
More recently, analogous systems have been developed in
yeast143 and mammalian cells144−154 that should more
accurately reﬂect toxicological responses in humans. In one of
the key examples, the promoter and regulatory sequences of a
growth arrest and DNA damage gene, GADD45a, the
expression of which is upregulated in human cells in response
to DNA damage, were coupled to the expression of GFP in a
human lymphoblastoid TK6 cell line.144 This “GreenScreen
HC” test is sensitive to many types of genotoxins, including
aneugens which are not routinely detected in bacterial
genotoxicity screens. GreenScreen HC also compares well to
alternative genotoxicity tests such as the SOS-Chromotest and
Mini Ames II.155−160 This has been the forerunner of a number
of similar reporter gene assays based on linking the regulatory
sequences for some protein involved in a response to toxic
insult (multiple mechanisms of genotoxicity, oxidative stress,
etc.) to a ﬂuorescent or luminescent reporter gene.143,145−154
These have been reviewed recently elsewhere161 and will not be
covered in detail here. Again, however, most lack any
endogenous bioactivation system to enable the detection of
toxicity due to metabolites rather than parent compounds.
Exceptions are tests developed in metabolically competent
HepG2 cells expressing at least some phase I and II activities146
and in primary human hepatocytes.152
The explosion in genotoxicity and other reporter gene
screening assays in recent years based on signaling pathways for
responses to toxic stimuli161 highlights the need for an
understanding of the importance of and interplay between
speciﬁc key events in toxicological cascades, i.e., adverse
outcome pathways162 in order to apply the reductionist
approach of synthetic biology. Notwithstanding these examples,
much toxicology testing is dependent on high content
screening in mammalian cell culture, and tissue- or animal-
based systems.163−166 While synthetic biology approaches
would be advantageous in replacing mammalian cell-based
and animal testing with less costly and more ethically
acceptable alternatives, toxicity is a complex end point.
Modeling of toxicological processes must include the behavior
of systems at low concentrations and the existence or otherwise
of threshold eﬀects.167 However, inspiration can be drawn from
phenotypic screening systems developed for drug discovery, in
which synthetic biology approaches are increasingly being
incorporated (reviewed in ref 168). Conceivably, the depend-
ence of toxicological outcomes on multiple factors can be
captured by synthetic AND gates,169 and thresholds can be
introduced by careful choice of components and clever design
of circuits.
■ SYNTHETIC BIOLOGY IN CLINICAL TOXICOLOGY:
PUTTING IT ALL TOGETHER FOR HUMAN HEALTH
Numerous applications of synthetic biology can be envisaged in
clinical toxicology. At one extreme, the treatment of acute toxic
chemical exposure (e.g., drug overdose, poisoning, or
medication error) could be augmented by delivering engineered
enzymes able to detoxify the toxin. For example, engineered
P450 enzymes could be delivered in virus-like-particles
(VLPs),170 which are simple, well-deﬁned, self-assembling
nanostructures that show promise for many applications.171
The judicious choice of a VLP might enable targeting of speciﬁc
tissues to enhance detoxiﬁcation in situ of chemicals that are
concentrated in or toxic to particular organs.
Analogous approaches could enable pre-emptive treatment of
possible iatrogenic poisoning. Patients with genetic poly-
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morphisms in certain P450s are at risk of accumulating toxic
levels of drugs when given standard doses. An alternative to
avoiding the aﬀected drugs or adjusting doses (which may be
diﬃcult for orally administered drugs or in an outpatient
setting) might be the use of implanted optogenetic devices, like
that developed for blood glucose control,172 that could be
triggered to express an engineered P450 as and when required.
In these devices, melanopsin, which detects blue light, is
expressed in a mammalian cell system. When appropriately
illuminated, melanopsin triggers a signal transduction pathway
leading to the expression of a target gene. In this case, the target
would be an engineered P450 enzyme able to eﬃciently
detoxify the toxin of interest. Alternatively, designer signal
transduction pathways could be envisaged analogous to that
developed for experimental treatment of metabolic syn-
drome.173 Ideally, both of these types of system would be
delivered in subcutaneous, semipermeable, encapsulated, cell
implants, protected from the immune system and readily
irradiated with blue light.
Moving beyond the “eﬀector” and “sensor-reporter” (e.g.,
simple biosensor) paradigms to the “sensor-eﬀector” model
(Figure 2), synthetic biology devices of greater complexity can
be envisaged that combine detection and treatment of toxicity,
“detect and protect” systems for enhanced clearance of toxins
from the body when needed. Here, the input would be the
chemical of interest, and the main output would be the
expression of an enzyme to degrade the toxin. This is analogous
to “prosthetic networks”, e.g., for controlling blood urate
concentrations (reviewed in ref 174); such smart systems
would couple the detection of a toxic chemical to the triggering
of expression of a protective mechanism. In this case, use could
be made of existing “bioparts” in the form of the nuclear
receptors that sense many diverse xenobiotics and their
corresponding response elements: the gene for a P450
engineered to be highly eﬃcient at detoxiﬁcation of the
chemical of interest could be put under the control of this
system such that its expression was induced when required.
Engineering of the nuclear receptor could potentially enhance
its speciﬁcity toward toxins of particular importance and limit
unwanted cross-talk with other chemicals. An alternative type
of switch is exempliﬁed by Erkelenz et al., who attached the two
domains of P450BM3 to short oligonucleotides.
175 In this
system, the P450 activity could be tuned by the presence of
competing oligonucleotides (or potentially miRNAs). How-
ever, the need to conjugate the P450 with an oligonucleotide
currently limit this approach to in vitro applications.
■ CONCLUSION AND FUTURE PERSPECTIVES
It should be clear from the discussion above that there are
abundant opportunities to deploy synthetic biology approaches
in toxicology (Figure 2), as in other areas of the biomedical and
life sciences. Moreover, the applications outlined above for
P450 enzymes could, in many cases, just as easily be envisaged
for other proteins of toxicological interest. So the question
arises as to why there has been relatively little uptake of
synthetic biology to solve toxicological problems since its
emergence as a discipline, outside of conventional protein
engineering approaches for drug development.
As noted above, for synthetic biology devices using P450s to
be economically feasible, P450s need to be speciﬁc for the
reaction/chemical in question and, where catalysis is needed,
able to sustain high turnovers with cheap sources of electrons.
More eﬀort is needed in the engineering of P450s to these
ends. A key property for all applications is thermostability, as
this determines the half-life of the protein at ambient as well as
elevated temperatures and thereby the eﬀective lifetime of the
device or system.
One major limitation has been the lack of reliable, “drop-in”
expression systems, which on average can be expected to work
for most P450s, so that the diversity of forms found in Nature
can be exploited. The heterologous expression of P450s
remains an “art” in many respects, despite more than 20
years of continuous study. The guidelines for achieving success
in expressing P450s in bacteria or yeast remain somewhat
empirical; it is not possible to predict a priori which P450s will
be straightforward to express and which problematic or which
of many alternative approaches will work and why. There have
been some recent successes in this regard,176 but it remains to
be proven whether these advances will be broadly applicable.
The ideal, “all-purpose” expression system would include
modular, interchangeable redox partners, the levels of which
could be controlled independently of the P450, and automatic
coexpression of useful chaperones (e.g., genomic engineering of
groES/EL to be induced concurrently with the P450).
Another important gap is the lack of a truly convenient host
organism for P450-based studies. The advantage of E. coli is its
simplicity and the absence of endogenous P450s, but functional
expression is fraught by the problems outlined above. Many
eukaryotes are better suited for functional expression, but
analyses can be confounded by native P450s, and expression
yields may be harder to detect and optimize. Moreover,
mammalian cell systems are less well characterized as hosts for
synthetic biology applications than E. coli or Saccharomyces
cerevisiae. Other aspects to consider would include membrane
composition, viability of the cells without native P450s,
engineering for heme and ﬂavin supply (i.e., a superior host
cell that diverts resources toward P450 support, reducing media
costs), and engineered chromosomal coexpression of beneﬁcial
chaperones. In this regard, the development of a simpliﬁed,
“minimalist” cell, one of the aims of synthetic biology, could be
explored. One might envisage ultimately the creation of a cell
line that expresses the full battery of metabolic enzymes and
transporters found in the human hepatocyte, for example, at
levels that could be tuned to mimic diﬀerent genotypes. Such a
cell, after extensive validation, might eventually supplant
hepatocytes as a test system for preclinical drug metabolism
studies.
The most fertile area for synthetic biology in the short term
is likely to be in biocatalysis, for the production of metabolites
and other chemicals. This represents the “lowest hanging fruit”,
and implementing solutions from problems solved here will
facilitate the approaches to other problems. Another short-term
target should be the introduction of metabolic (bioactivation)
systems, including but not limited to P450s, into the newer
mammalian genotoxicity and other screening systems. For
toxicity assays, it is important that the host cell expresses
mammalian proteins, e.g., in the pathways that are activated
upon perception of a toxic insult. Again, a simpliﬁed, “drop-in”,
engineered host cell would be useful, in which one could
reasonably anticipate functional expression to be straightfor-
ward and easily quantiﬁed, and which recapitulates the required
pathways for manifestation of the toxicity.
For less straightforward applications, more needs to be done
to evaluate the component bioparts and how they behave.
Synthetic genetic circuits are diﬃcult to develop for several
reasons:177 precise tuning is required to optimize the level of
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expression of diﬀerent elements; regulatory elements are often
toxic to the host cell; cross-talk between elements of a circuit or
with other cellular components can impair function of the
circuit; the design rules are not well characterized for biological
circuits; and the physical construction of circuits composed of
many parts from diﬀerent biological contexts can be problem-
atic. For most purposes in toxicology, it may be possible to
design circuits in which fewer factors need to be optimized than
in conventional synthetic biology applications. This is because
natural “biobricks” exist in the form of the receptors,
transcription factors, and response elements that mediate the
response to toxicity, and are, by deﬁnition, active in the relevant
physiological or toxicological concentration range. However,
again, it will be important to choose an appropriate host cell
“chassis” and to tune the expression of the various components.
Advances in synthetic biology in the past decade, particularly
with respect to metabolic engineering, have simpliﬁed the
development of organisms that produce valuable chemicals and
provided pathways for optimization. This has stimulated the
transfer from lab bench to practical application. On the other
hand, many of the same principles can be applied to organisms
engineered for purposes such as bioremediation, but there has
been minimal progress toward practical application of synthetic
biology in these applications, despite the wealth of data
available on suitable catabolic enzymes including engineered
P450s. In order to understand the lack of progress in practical
applications of synthetic biology more broadly, compared to
the recent boom in synthetic biology for bioproduction, it is
helpful to explore the situation concerning bioremediation, as
an example in which societal and economic drivers are quite
diﬀerent from those for chemical synthesis.
Modern bioproduction and prospects for eﬀective bioreme-
diation rely heavily on genetically modiﬁed organisms (GMOs),
which are regulated in most countries in order to prevent
unforeseen consequences of widespread release in the environ-
ment. Consequently, bioproduction using engineered microbes
that can be fully contained in an industrial fermentation has
ﬂourished while the deployment of engineered plants has been
relatively slow due to the greater risk of unintended spread and
cross-pollination with non-GMO species. In the case of
bioremediation, most practical applications would require
deployment in the ﬁeld at contaminated sites, which
complicates the development process in most jurisdictions.
Additionally, the market incentives for the development and
deployment of bioremediation solutions are not clear. At face
value, the market for bioremediation technologies would appear
vast, but the picture is complicated by the varying types of
compounds that require bioremediation and the distribution of
sites across legal jurisdictions and between public and private
ownership. For comparison, the development of organisms for
the production of advanced biofuels has been accelerated by
clearly deﬁned government incentives and by what is eﬀectively
a permanent global market for the consumption of energy. No
such situation exists for bioremediation. The diversity of
contaminated sites, the size of each market, and the regulatory
barriers to entry are unclear. It is diﬃcult to imagine
formulating a business case for private investment in developing
bioremediation technologies, and it is unclear whether
bioremediation research and development are capable of
attracting signiﬁcant government funding when it is diﬃcult
to deﬁne the scope of the problem. It might be argued that the
most valuable contribution of scientists now to advance
bioremediation technology is not necessarily to discover and
develop new enzymes but to create and promote conversation
about bioremediation with the public, government oﬃcials, and
private companies.
Engagement with the wider community has been taken very
seriously in the development of the synthetic biology ﬁeld, e.g.,
through the iGEM (International Genetically Engineered
Machine) competitions, in an eﬀort to bring the public along
with the tide of innovation enabled by synthetic biology, in the
hope of avoiding mistakes made in the past. The fact that novel
toxicological applications feature so commonly in the topics
chosen by iGEM teams suggest that the scientists of the future
see synthetic biology as an important means by which to
address problems in the clinical, experimental, and environ-
mental ﬁelds. While it is impossible to predict where the ﬁeld
will go in the next 30 years, the energy and enthusiasm with
which synthetic biology is being taken up by the next
generation of scientists suggests that there will be more things
in heaven and Earth than can be dreamt of with our current
philosophy.
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